Combinaisons de thérapies anti-HER2: deux balles pour une même cible !GONCALVES, Anthony.Bulletin du cancer. 2012, Vol 99, Num 9, pp 813-814, issn 0007-4551, 2 p.Article

Her-2/neu overexpression and amplification in uterine papillary serous carcinomaSLOMOVITZ, Brian M; BROADDUS, Russell R; BURKE, Thomas W et al.Journal of clinical oncology. 2004, Vol 22, Num 15, pp 3126-3132, issn 0732-183X, 7 p.Conference Paper

Surexpression de HER2: un dictat ? = Overexpression of HER2: a dictat?COTTU, P.Société Française de Sénologie et de Pathologie Mammaire. Journées. 2011, pp 168-173, isbn 978-2-8178-0248-0, 1Vol, 6 p.Conference Paper

Is HER2/neu expressed in nonepithelial ovarian malignancies?MENCZER, Joseph; SCHREIBER, Letizia; CZERNOBILSKY, Bernard et al.American journal of obstetrics and gynecology. 2007, Vol 196, Num 1, pp 79-80, issn 0002-9378, 2 p.Article

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

Downregulation of Muc1 in MMTV-c-Neu tumorsADRIANCE, Melissa C; GENDLER, Sandra J.Oncogene (Basingstoke). 2004, Vol 23, Num 3, pp 697-705, issn 0950-9232, 9 p.Article

Radionuclide therapy of HER2-positive microxenografts using a ¹⁷⁷Lu-labeled HER2-specific affibody moleculeTOLMACHEV, Vladimir; ORLOVA, Anna; WENNBORG, Anders et al.Cancer research (Baltimore). 2007, Vol 67, Num 6, pp 2773-2782, issn 0008-5472, 10 p.Article

Par complex in cancer : a regulator of normal cell polarity joins the dark sideARANDA, V; NOLAN, M. E; MUTHUSWAMY, S. K et al.Oncogene (Basingstoke). 2008, Vol 27, Num 55, pp 6878-6887, issn 0950-9232, 10 p.Article

Modified direct-double-differential PCR for gene dosage quantification of HER2ZACZEK, Anna; WELNICKA-JASKIEWICZ, Marzena; BUERGER, Horst et al.Oncology reports. 2005, Vol 13, Num 5, pp 971-975, issn 1021-335X, 5 p.Article

Two Dimensions in Targeting HER2MOASSER, Mark M.Journal of clinical oncology. 2014, Vol 32, Num 19, pp 2074-2077, issn 0732-183X, 4 p.Article

ErbB2 Trafificking and Degradation Associated with K48 and K63 PolyubiquitinationMARX, Corina; HELD, Jason M; GIBSON, Bradford W et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 9, pp 3709-3717, issn 0008-5472, 9 p.Article

Clinical relevance of HER-2/neu expression in germ-cell testicular tumorsMANDOKY, Laszlo; GECZI, Lajos; BODROGI, Istvan et al.Anticancer research. 2004, Vol 24, Num 4, pp 2219-2224, issn 0250-7005, 6 p.Article

Immunobiology of Her-2/Neu transgenic micePANNELLINI, Tania; FORNI, Guido; MUSIANI, Piero et al.Breast disease. 2004, Vol 20, pp 33-42, issn 0888-6008, 10 p.Article

A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas : comparison with HER-2/CEP17 ratio systemMRHALOVA, Marcela; KODET, Roman.Journal of cancer research and clinical oncology. 2007, Vol 133, Num 5, pp 321-329, issn 0171-5216, 9 p.Article

Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer PatientsOCCHIPINTI, Sergio; SPONTON, Laura; AMICI, Augusto et al.Clinical cancer research (Print). 2014, Vol 20, Num 11, pp 2910-2921, issn 1078-0432, 12 p.Article

Genetic Ablation of the Fatty Acid―Binding Protein FABP5 Suppresses HER2-Induced Mammary TumorigenesisLEVI, Liraz; LOBO, Glenn; DOUD, Mary Kathryn et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 15, pp 4770-4780, issn 0008-5472, 11 p.Article

β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor ProgressionSCHADE, Babette; LESURF, Robert; GIGUERE, Vincent et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 14, pp 4474-4487, issn 0008-5472, 14 p.Article

In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in agingPROVINCIALI, Mauro; BARUCCA, Alessandra; PIERPAOLI, Elisa et al.Cancer immunology and immunotherapy. 2012, Vol 61, Num 3, pp 363-371, issn 0340-7004, 9 p.Article

Outgrowth of single oncogene-expressing cells from suppressive epithelial environmentsLEUNG, Cheuk T; BRUGGE, Joan S.Nature (London). 2012, Vol 482, Num 7385, pp 410-413, issn 0028-0836, 4 p.Article

Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA GenesLI, Long-Yuan; CHEN, Hsiuyi; LAI, Chien-Chen et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 12, pp 4269-4279, issn 0008-5472, 11 p.Article

Cyclin D3 Compensates for the Loss of Cyclin D1 during ErbB2-Induced Mammary Tumor Initiation and ProgressionQIAN ZHANG; SAKAMOTO, Kazuhito; CHENGBAO LIU et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 24, pp 7513-7524, issn 0008-5472, 12 p.Article

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodiesSCHROHL, Anne-Sofie; CHRISTIAN PEDERSEN, Hans; STEEN JENSEN, Sussie et al.Histopathology. 2011, Vol 59, Num 5, pp 975-983, issn 0309-0167, 9 p.Article

Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of CtenBARBIERI, Isaia; PENSA, Sara; PROVERO, Paolo et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 6, pp 2558-2567, issn 0008-5472, 10 p.Article

Copine-III interacts with ErbB2 and promotes tumor cell migrationHEINRICH, C; KELLER, C; BOULAY, A et al.Oncogene (Basingstoke). 2010, Vol 29, Num 11, pp 1598-1610, issn 0950-9232, 13 p.Article

HER-2 Signaling, Acquisition of Growth Factor Independence, and Regulation of Biological Networks Associated with Cell TransformationBOLLIG-FISCHER, Aliccia; DZIUBINSKI, Michele; BOYER, Alaina et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 20, pp 7862-7873, issn 0008-5472, 12 p.Article